• FR

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Reported Friday, MannKind’s Under-10-Second Furoscix ReadyFlow Autoinjector Shows Urine Output Comparable To IV Furosemide In New HFSA 2026 Analyses, Supporting Outpatient Edema Management In Heart Failure And CKD

    Benzinga·10/12/2026 08:20:05
    Diffusion vocale
    • New analyses on Furoscix ReadyFlow PK/PD performance delivered via an autoinjector demonstrated comparable urine output to IV furosemide
    • Consistent bioavailability, diuresis and natriuresis across injection sites support flexible administration in clinical practice
    • Cross-study analysis demonstrates comparable diuretic and natriuretic responses between Furoscix ReadyFlow and Furoscix® (furosemide) On-body Infusor, supporting a seamless transition to ReadyFlow
    • Data presentations build on the July 2026 FDA approval and U.S. launch of Furoscix ReadyFlow, the first and only autoinjector delivering IV-equivalent diuretic therapy for heart failure- and CKD-related edema (fluid overload)